Compugen (NASDAQ:CGEN) CEO Sells $12,431.25 in Stock

Compugen Ltd. (NASDAQ:CGEN) CEO Eran Ophir sold 5,625 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $2.21, for a total value of $12,431.25. Following the transaction, the chief executive officer directly owned 11,375 shares in the company, valued at approximately $25,138.75. This represents a 33.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Compugen Stock Up 2.7%

Shares of CGEN stock opened at $2.26 on Friday. The stock’s 50-day moving average price is $1.96 and its 200 day moving average price is $1.77. The stock has a market capitalization of $213.68 million, a PE ratio of 6.11 and a beta of 2.77. Compugen Ltd. has a 52-week low of $1.13 and a 52-week high of $2.38.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. The company had revenue of $67.33 million during the quarter, compared to analysts’ expectations of $14.30 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%. Analysts expect that Compugen Ltd. will post -0.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CGEN. Wall Street Zen raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. HC Wainwright began coverage on shares of Compugen in a report on Wednesday, January 7th. They issued a “buy” rating and a $4.00 target price on the stock. Truist Financial upgraded shares of Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Compugen currently has an average rating of “Moderate Buy” and a consensus target price of $4.00.

Institutional Trading of Compugen

Several large investors have recently bought and sold shares of CGEN. Renaissance Technologies LLC raised its stake in shares of Compugen by 3.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock worth $2,229,000 after buying an additional 51,565 shares during the last quarter. Jane Street Group LLC grew its stake in Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after acquiring an additional 359,785 shares during the last quarter. State Street Corp increased its holdings in Compugen by 3.9% during the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after acquiring an additional 14,701 shares in the last quarter. Two Sigma Investments LP increased its holdings in Compugen by 10.6% during the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 18,929 shares in the last quarter. Finally, Marshall Wace LLP raised its position in Compugen by 135.7% during the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 61,202 shares during the last quarter. Institutional investors and hedge funds own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.